Table 1.
Characteristics of the study population.
| Methicillin antibiogram profile |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Factor/Strata | n (%) | Resistant | Susceptible | Unknown | ||||||
| UK | 722 (18.3%) | 181 (25.1%) | 451 (62.5%) | 90 (12.5%) | ||||||
| The Netherlands | 386 (9.8%) | 40 (10.4%) | 87 (22.5%) | 259 (67.1%) | ||||||
| Norway | 268 (6.8%) | 51 (19%) | 165 (61.6%) | 52 (19.4%) | ||||||
| Japan | 245 (6.2%) | 32 (13.1%) | 190 (77.6%) | 23 (9.4%) | ||||||
| USA | 234 (5.9%) | 113 (48.3%) | 53 (22.6%) | 68 (29.1%) | ||||||
| Switzerland | 204 (5.2%) | 34 (16.7%) | 170 (83.3%) | 0 (0%) | ||||||
| Australia | 195 (4.9%) | 138 (70.8%) | 51 (26.2%) | 6 (3.1%) | ||||||
| Germany | 139 (3.5%) | 56 (40.3%) | 63 (45.3%) | 20 (14.4%) | ||||||
| France | 131 (3.3%) | 51 (38.9%) | 55 (42%) | 25 (19.1%) | ||||||
| Spain | 113 (2.9%) | 64 (56.6%) | 46 (40.7%) | 3 (2.7%) | ||||||
| China | 100 (2.5%) | 64 (64%) | 30 (30%) | 6 (6%) | ||||||
| Gambia | 100 (2.5%) | 0 (0%) | 100 (100%) | 0 (0%) | ||||||
| Iran | 87 (2.2%) | 82 (94.3%) | 5 (5.7%) | 0 (0%) | ||||||
| Italy | 79 (2%) | 45 (57%) | 27 (34.2%) | 7 (8.9%) | ||||||
| Thailand | 64 (1.6%) | 33 (51.6%) | 15 (23.4%) | 16 (25%) | ||||||
| Ireland | 56 (1.4%) | 17 (30.4%) | 34 (60.7%) | 5 (8.9%) | ||||||
| Portugal | 56 (1.4%) | 33 (58.9%) | 9 (16.1%) | 14 (25%) | ||||||
| Denmark | 51 (1.3%) | 9 (17.6%) | 35 (68.6%) | 7 (13.7%) | ||||||
| Bulgaria | 51 (1.3%) | 1 (2%) | 0 (0%) | 50 (98%) | ||||||
| Poland | 49 (1.2%) | 13 (26.5%) | 33 (67.3%) | 3 (6.1%) | ||||||
| Canada | 48 (1.2%) | 9 (18.8%) | 37 (77.1%) | 2 (4.2%) | ||||||
| Brazil | 42 (1.1%) | 10 (23.8%) | 22 (52.4%) | 10 (23.8%) | ||||||
| Sweden | 38 (1%) | 22 (57.9%) | 2 (5.3%) | 14 (36.8%) | ||||||
| Taiwan | 33 (0.8%) | 20 (60.6%) | 1 (3%) | 12 (36.4%) | ||||||
| Gabon | 30 (0.8%) | 0 (0%) | 30 (100%) | 0 (0%) | ||||||
| Finland | 30 (0.8%) | 27 (90%) | 3 (10%) | 0 (0%) | ||||||
| Other | 374 (9.5%) | 179 (47.9%) | 106 (28.3%) | 89 (23.8%) | ||||||
| Country | Unknown | 15 (0.4%) | 5 (33.3%) | 4 (26.7%) | 6 (40%) | |||||
| Total | 3940 (100%) | 1329 (33.7%) | 1824 (46.3%) | 787 (20%) | ||||||
| Female | 586 (14.9%) | 172 (29.4%) | 360 (61.4%) | 54 (9.2%) | ||||||
| Male | 633 (16.1%) | 238 (37.6%) | 326 (51.5%) | 69 (10.9%) | ||||||
| Gender | Unknown | 2721 (69.1%) | 919 (33.8%) | 1138 (41.8%) | 664 (24.4%) | |||||
| <=2000 | 953 (24.2%) | 335 (35.2%) | 484 (50.8%) | 134 (14.1%) | ||||||
| 2001 to 2004 | 1143 (29%) | 465 (40.7%) | 603 (52.8%) | 75 (6.6%) | ||||||
| 2005 to 2007 | 945 (24%) | 247 (26.1%) | 390 (41.3%) | 308 (32.6%) | ||||||
| >=2008 | 685 (17.4%) | 206 (30.1%) | 277 (40.4%) | 202 (29.5%) | ||||||
| Calendar year | Unknown | 214 (5.4%) | 76 (35.5%) | 70 (32.7%) | 68 (31.8%) | |||||
| Antibiogram results | ||||||||||
| Oxacillin- |
||||||||||
| Methicillin vs. Oxacillin | Resistant | Susceptible | Unknown | |||||||
| Resistant |
191 | 2 | 374 | |||||||
| Susceptible |
47 | 306 | 606 | |||||||
| Methicillin- | Unknown |
63 | 40 | 376 | ||||||